Trellis Bioscience is a clinical-stage private biotech company discovering and developing human antibodies against infectious diseases and cancer. TRL1068 completed a landmark Phase 1 clinical study in patients with chronic periprosthetic joint infections. TRL345 is in a Phase 1 safety study in healthy adult volunteers. While initially focusing on anti-viral antibodies, the Company built a robust, semi-automatic, well validated platform known as CellSpot™ for which the needle in the haystack analogy perfectly applies to describe the unique ability to identify and recover 1 out of 1 million B-cells that produce desirable human antibodies for therapeutic use. At the end of 2009, Trellis closed a landmark deal to license a pre-IND stage anti-RSV mAb to MedImmune. In 2014, we licensed our influenza A and B program to ContraFect, Inc. Current programs include an anti-human cytomegalovirus (HCMV) mAb for transplant patients, a bacterial biofilm disrupting human antibody for the treatment of chronic Gram+ and Gram- infections, and human antibodies against immune check point modulators (ICMs) including LAG-3, TIM-3, KIR2, B7-H3, VISTA and CEACAM-1 for the treatment of cancer. The CellSpot platform allowed us to discover fully matured IgG anti-ICM antibodies from healthy donors with no known cancer. The immune surveillance concept suggest that the immune system of healthy individuals fights emerging tumors. leaving a footprint in the memory B cell compartment, which is detectable by a sensitive technology platform such as CellSpot. The cancer mAbs were licensed to Relevant Biosciences.

Clinovo is a CRO based in Sunnyvale with an impressive team of experts in biostatistics, clinical data management and electronic data capture. The Clinovo team has a strong track record in IND, NDA, BLA, IDE, PMA and 510k filings.

A-Cube was acquired by Trellis Bioscience in 2013.A-Cube is a leader in identifying B-cell epitopes, which are the binding sites for monoclonal antibodies. By generating comprehensive B-cell epitope maps of proteins we develop plans to de-immunize therapeutic proteins. We have successfully lowered the immunogenicity score in a model protein and currently focus on de-immunizing factor VIII and enzyme replacement therapies (ERTs). We expect that a de-immunized factor VIII therapy would not be inhibited by neutralizing antibody (inhibitors) that have developed in a subset of hemophilia patients after exposure to current factor VIII therapy. This application potentially addresses a huge medical need for hemophilia patients.ERT therapy is often accompanied by the occurrence of neutralizing antibodies. Our novel approach to de-immunize ERTs will reduce the neutralizing effect of neutralizing antibodies that already exist in patients with lysosomal storage diseases.Other applications to de-immunize proteins include gene therapy vector AAV. In gene therapy, neutralizing antibodies are a limiting factor. We also apply the technology in an opposite manner, namely to concentrate immunogenic parts of viral proteins in vaccine prototypes. We are currently creating a blueprint to a universal influenza vaccine. The third application has been reduced to practice several times: raise antibodies against newly identified B-cell epitopes. While differentiating against traditional wet lab technologies through a more focused and direct approach, in addition our technology helps to prioritize epitopes and generate antibodies against novel B-cell epitopes.

A-Cube's mission:Apply proprietary bioinformatics technology in various areas to generate IP, license/partner these programs with pharma/biotech companies Partner technology platform with pharma/biotech companies to improve their mAbs and vaccines in the pipeline, and to generate new IPDevelop two drug candidates and advance them to generate meaningful clinical signals, then seek partnership for development and commercialization

Aridis Pharmaceuticals focuses on product candidates targeting infectious diseases and on advanced formulation and delivery technologies to improve the effectiveness of proprietary products. One of Aridis's product candidates is Aerucin, a human monoclonal antibody against Pseudomonas aeruginosa. It is in a pre-IND stage and has the potential to be best in class for the treatment of pseudomonas infections which are an increasing burden to the healthcare system. The mechanism of action is novel and appears suitable to combination therapy with antibiotics.

BIOptima Advisors is a consulting firm dedicated to improving decision making in therapeutics-based companies. Our clients are biotechnology companies, pharmaceutical companies, and venture capital firms. We add value by leveraging our operational and investment experience with superior decision analysis techniques.

ARKc3, Inc. is privately owned company with a primary focus on developing and commercializing healthcare IT solutions.

Stefan Ryser created a more efficient and functional clinical organization while the Chief Medical Officer reported to him.Reduced non-critical support functions in R&D.Prioritized drug discovery pipeline and focused research projects.Generated new research ideas and business opportunities for the company's proprietary computational drug screening technology.Worked closely with head of business development, Marc Steuer, and generated preliminary leads for BD opportunities.Stefan Ryser has resigned effective August 1, 2009 as Senior Vice President of Corporate Strategy. Telik is grateful to Dr. Ryser's contributions as an employee and as a member of the company's Board of Directors for the past 11 years. Dr. Ryser will start a consulting business in a joint effort with one of his former business partners, and has agreed to provide consulting services to the Company for a limited period of time after his resignation becomes effective.

Stefan Ryser was among three members of the board of directors that left the board in 2009.

Stefan was a General Partner of Bear Stearns Health Innoventures (BSHI), a New York-based $212 million biotech venture fund which he co-founded with Elizabeth A. Czerepak, Fritz R. Buhler, M.D. and Jürgen Drews, M.D.He was also a Managing Director of Bear Stearns Asset Management which is now part of JP Morgan Chase & Co.BSHI was lead investor in all 13 portfolio companies, of which six went public and two were acquired for substantial premiums. Portfolio companies included Affymax, Achillion Pharmaceuticals, Advancis Pharmaceutical, Agensys, AGY Therapeutics, Corus, PharmAthene, Raven Biotechnologies and Tolerx.Elizabeth A. Czerepak and Stefan co-authored an article with the title 'Drug approvals and failures: implications for alliances' (published in Nature Reviews/Drug Discovery, vol. 7, pp197-198, March 2008).New York, New York

Basel, Switzerland

International Biomedicine Management Partners (IBMP) managed a Switzerland-based $60 million biotech venture fund which Stefan co-founded with Fritz R. Buhler, M.D. and Jürgen Drews, M.D. IBMP was lead investor in ten of 12 portfolio companies, of which 9 went public and 3 were acquired. Portfolio companies included Arena Pharmaceuticals, Allos Therapeutics, Artemis Pharmaceuticals, Coelacanth, Cytokinetics, Exelixis, Genaissance Pharmaceuticals, IntraBiotics Pharmaceuticals, Orchid Biosciences, Scriptgen, Sunesis Pharmaceuticals and Telik.Stefan was a member of the board of the R.Geigy Foundation, an organization that supports the Swiss Tropical Institute in Basel, Switzerland (1999-2002)Basel, Switzerland

Basel, Switzerland

Stefan was a consultant for BioRegio, a program of the German Federal Ministery of Research and Education (BMBF) in Bonn to fund biotech companies and for BioChance, an initiative of the German government to support biotech start-up companies (1996-2001) Basel, Switzerland

Basel, Switzerland

Strategy, assessment and acquisition of novel technologies for drug discovery and preclinical R&D. Stefan was a member of the Joint Steering Committee of Roche and Millennium Pharmaceuticals (1994 and 1995)Stefan served as the Global R&D President's liaison to Genentech for new preclinical project collaborations and to the Roche Institute for Molecular Biology (RIMB).Jürgen Drews, M.D., President of Global R&D and Stefan co-authored several articles, including 'The Innovation Deficit in the Pharmaceutical Industry' (published 1996 in Drug Information Journal) and 'Known Targets for Commercial Drugs' (published 1997 in Nature Biotechnology).Nutley, New Jersey

Nutley, New Jersey

Public relations for biotechnology in Switzerland.Vice Chairman of Brussels, Belgium-based Strategy Committee, Senior Advisory Group Biotechnology (SAGB), now EuropaBio, (1991-1997)President, Naturforschende Gesellschaft Basel (1992)Basel, Switzerland